Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study.

ABSTRACT:

Objective

The Foundation for National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify and qualify biomarkers to support drug development in knee osteoarthritis (OA). The PROGRESS OA study aims to externally validate prognostic biomarkers identified in the earlier Phase I study.

Design

PROGRESS OA included data from the control arms of several completed randomized controlled trials (RCTs) for knee OA. The primary outcome was medial or lateral joint space width loss (JSWL) ≥0.7 ​mm. Secondary outcomes included medial or lateral JSWL combined with symptomatic progression. Nine biochemical biomarkers identified in Phase I were included here. Logistic regression with elastic net selection examined associations between baseline biomarkers and outcomes over 12

SUBMITTER: Collins JE 

PROVIDER: S-EPMC12495463 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature